April 2025 – BioLinq, a US-based medical technology innovator, has announced the launch of its first skin-applied continuous glucose monitor (CGM), aiming to reshape diabetes care through non-invasive biosensing. The company’s breakthrough device measures glucose levels beneath the skin without any needle insertion, offering a painless and user-friendly alternative to conventional CGMs.
The wearable sensor, which has received Breakthrough Device designation from the US FDA, is designed for a five-day wear period and transmits real-time glucose readings to a mobile app. By eliminating skin penetration, BioLinq's platform addresses a key barrier to CGM adoption—user discomfort—while maintaining clinically relevant accuracy.
The device is expected to appeal to both type 2 diabetics and prediabetic individuals seeking less invasive monitoring solutions. BioLinq will use this initial launch phase to collect additional clinical data and begin early commercialization efforts in select US markets.
According to NextGen Intelligence Stats, the glucose biosensors market is on track for significant growth, fueled by rising global diabetes prevalence, demand for real-time monitoring, and innovations in wearable biosensor technology. The market is evolving rapidly as healthcare shifts toward personalized, preventive, and digital health solutions.
With its skin-applied biosensor, BioLinq is positioned to lead the next generation of CGM innovation—combining comfort, technology, and clinical utility in a scalable format that could reshape glucose monitoring globally.
Explore more about the glucose biosensors market here:
👉Glucose Biosensors Market – NextGen Intelligence Stats
© NextGen Intelligence Stats and Consulting LLP All rights reserved.